Coblopasvir

CAS No. 1312608-46-0

Coblopasvir( KW136 | KW-136 )

Catalog No. M11255 CAS No. 1312608-46-0

Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 423 Get Quote
10MG 620 Get Quote
25MG 972 Get Quote
50MG 1314 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Coblopasvir
  • Note
    Research use only, not for human use.
  • Brief Description
    Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.
  • Description
    Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.HCV Infection Phase 3 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    KW136 | KW-136
  • Pathway
    Microbiology/Virology
  • Target
    HCV
  • Recptor
    HCV
  • Research Area
    Infection
  • Indication
    HCV Infection

Chemical Information

  • CAS Number
    1312608-46-0
  • Formula Weight
    782.899
  • Molecular Formula
    C41H50N8O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC)N[C@@H](C(C)C)C(N1[C@H](C2=NC(C3=CC=C(C4=C5OCOC5=C(C6=CNC([C@H]7N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC7)=N6)C=C4)C=C3)=CN2)CCC1)=O
  • Chemical Name
    methyl {(2S)-1-[(2S)-2-(4-{4-[7-(2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl)-2H-1,3-benzodioxol-4-yl]phenyl}-1Himidazol-2-yl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CEP37440

    CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).

  • Sofosbuvir

    Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

  • Telaprevir

    A potent, selective, covalent, orally bioavailable inhibitor of HCV NS3/4A protease with Ki of 7 nM.